RAB7A: A Potential Drug Target and Biomarker for the RAS Oncogene Family

Target Name: RAB7A

NCBI ID: G7879

RAB7A

RAB7A: A Potential Drug Target and Biomarker for the RAS Oncogene Family

The RAS (Ras-related gene) oncogene family is a gene family that plays a crucial role in cell signaling and has been implicated in various diseases, including cancer. The RAS gene family consists of four genes: RAB1, RAB2, RAB7A, and RASF1. RAB7A is a member of the RAS oncogene family and has been identified as a potential drug target and biomarker.

RAB7A is a 21-kDa protein that is expressed in various tissues, including brain, heart, and pancreas. It is a key regulator of the RAS/MAPK signaling pathway, which is involved in various cellular processes, including cell growth, differentiation, and survival. The RAB7A protein functions as a GTPase-activating protein (GAP) and is involved in the regulation ofMAPK signaling pathway.

The RAB7A gene has been studied extensively and has been shown to be involved in various cellular processes, including cell signaling, cell division, and cell survival. Several studies have shown that RAB7A is involved in the regulation of MAPK signaling pathway, which is a critical pathway involved in the regulation of cellular processes, including cell growth, differentiation, and survival.

MAPK signaling pathway is a critical pathway involved in the regulation of cellular processes, including cell growth, differentiation, and survival. The MAPK signaling pathway is a protein that is involved in the regulation of various cellular processes, including cell signaling, cell division, and cell survival. The MAPK signaling pathway is activated by the addition of a phosphate group to the MAPK protein, which then activates various downstream targets, including transcription factors, signaling proteins, and cytoskeletal proteins.

Several studies have shown that RAB7A is involved in the regulation of MAPK signaling pathway. For example, a study by Li et al. (2018) found that RAB7A was involved in the regulation of MAPK signaling pathway in cancer cells. The authors showed that RAB7A levels were increased in cancer cells and that inhibition of RAB7A led to a decrease in the activity of the MAPK signaling pathway.

Another study by Zhang et al. (2020) found that RAB7A was involved in the regulation of cell survival in cancer cells. The authors showed that RAB7A levels were increased in cancer cells and that inhibition of RAB7A led to a decrease in cell survival.

In addition to its involvement in the MAPK signaling pathway, RAB7A has also been shown to be involved in the regulation of various other cellular processes. For example, a study by Wang et al. (2019) found that RAB7A was involved in the regulation of cell migration in cancer cells. The authors showed that RAB7A levels were increased in cancer cells and that inhibition of RAB7A led to a decrease in cell migration.

Given its involvement in various cellular processes, including cell signaling, cell division, and cell survival, RAB7A is a potential drug target and biomarker. Researchers are currently exploring the use of small molecules and other compounds to inhibit the activity of RAB7A and to use it as a drug target in cancer treatment.

In conclusion, RAB7A is a member of the RAS oncogene family and has been shown to be involved in various cellular processes, including cell signaling, cell division, and cell survival. The RAB7A protein functions as a GTPase-activating protein (GAP) and is involved in the regulation of MAPK signaling pathway. Given its involvement in various cellular processes, RAB7A is a potential drug target and biomarker and has the potential to be used in cancer treatment. Further research is needed to fully understand the role of RAB7A in

Protein Name: RAB7A, Member RAS Oncogene Family

Functions: Small GTPase which cycles between active GTP-bound and inactive GDP-bound states. In its active state, binds to a variety of effector proteins playing a key role in the regulation of endo-lysosomal trafficking. Governs early-to-late endosomal maturation, microtubule minus-end as well as plus-end directed endosomal migration and positioning, and endosome-lysosome transport through different protein-protein interaction cascades. Plays a central role, not only in endosomal traffic, but also in many other cellular and physiological events, such as growth-factor-mediated cell signaling, nutrient-transportor mediated nutrient uptake, neurotrophin transport in the axons of neurons and lipid metabolism. Also involved in regulation of some specialized endosomal membrane trafficking, such as maturation of melanosomes, pathogen-induced phagosomes (or vacuoles) and autophagosomes. Plays a role in the maturation and acidification of phagosomes that engulf pathogens, such as S.aureus and M.tuberculosis. Plays a role in the fusion of phagosomes with lysosomes. Plays important roles in microbial pathogen infection and survival, as well as in participating in the life cycle of viruses. Microbial pathogens possess survival strategies governed by RAB7A, sometimes by employing RAB7A function (e.g. Salmonella) and sometimes by excluding RAB7A function (e.g. Mycobacterium). In concert with RAC1, plays a role in regulating the formation of RBs (ruffled borders) in osteoclasts. Controls the endosomal trafficking and neurite outgrowth signaling of NTRK1/TRKA (PubMed:11179213, PubMed:12944476, PubMed:14617358, PubMed:20028791, PubMed:21255211). Regulates the endocytic trafficking of the EGF-EGFR complex by regulating its lysosomal degradation. Involved in the ADRB2-stimulated lipolysis through lipophagy, a cytosolic lipase-independent autophagic pathway (By similarity). Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413). Required for vesicular trafficking and cell surface expression of ACE2 (PubMed:33147445). May play a role in PRPH neuronal intermediate filament assembly (By similarity)

The "RAB7A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB7A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets